ALNYLAM PHARMACEUTICALS, INC. Contracts & Agreements

Amendment No. 1 entered into as (Filed With SEC on August 3, 2023)

Letter Agreement, dated July 31, 2023, between Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D (Filed With SEC on August 3, 2023)

Form of Performance Stock Unit Award Agreement for Executive Officers under 2018 Stock Incentive Plan, as amended (Filed With SEC on May 4, 2023)

Form of Restricted Stock Unit Award Agreement for Executive Officers under 2018 Stock Incentive Plan, as amended (Filed With SEC on May 4, 2023)

Cross-License Agreement dated as of November 12, 2012 by and among the Registrant, Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) and Protiva... (Filed With SEC on February 23, 2023)

License and Collaboration Agreement dated as of February 3, 2013 by and among The Medicines Company and the Registrant (Filed With SEC on February 23, 2023)

Amendment No. 2 to License and Collaboration Agreement, dated as of October 31, 2022 between the Registrant and The Medicines Company (Filed With SEC on February 23, 2023)

Amendment to Purchase and Sale Agreement dated October 31, 2022 between BX Bodyguard Royalties L.P. and the Registrant (Filed With SEC on February 23, 2023)

Indenture, dated as of September 15, 2022, between the Registrant (Filed With SEC on October 27, 2022)

Indenture, dated as of September 15, 2022, between Alnylam Pharmaceuticals, Inc. and The Bank of New York Mellon, as trustee (Filed With SEC on September 16, 2022)

Form of Capped Call Transaction Confirmation (Filed With SEC on September 16, 2022)

Amended and Restated 2018 Stock Incentive Plan (Filed With SEC on July 28, 2022)

Letter Agreement between the Registrant and (Filed With SEC on April 28, 2022)

Forms of Nonstatutory Stock Option Agreements under 2018 Stock Incentive Plan, as amended (Filed With SEC on February 10, 2022)

Forms of Stock Unit Award Agreements under 2018 Stock Incentive Plan, as amended (Filed With SEC on February 10, 2022)

Amendment No. 1 to Co-Development Agreement between the Registrant and BXLS V Bodyguard PCP L.P. and BXLS Family Investment Partnership V ESC L.P. dated November 23, 2021 (Filed With SEC on February 10, 2022)

Employment Agreement, dated December 14, 2021, between Alnylam Pharmaceuticals, Inc. and Dr. Yvonne L. Greenstreet (Filed With SEC on December 20, 2021)

Letter Agreement between the Registrant and Laurie B. Keating dated September 6, 2021 (Filed With SEC on October 28, 2021)

Letter Agreement effective as of October 26, 2021 between the Company and John M. Maraganore, Ph.D (Filed With SEC on October 28, 2021)

Second Amendment to Lease entered into as of April 28, 2021 by and between BMR-Fresh Pond Research Park LLC and the Registrant (Filed With SEC on August 3, 2021)

Sponsored Research Agreement dated as of July 27, 2009 by and among the (Filed With SEC on August 3, 2021)

Amendment No. 1 to Sponsored Research Agreement dated as of July 27, 2009 (Filed With SEC on August 3, 2021)

Supplemental Agreement effective July 27, 2009 by and among the (Filed With SEC on August 3, 2021)

Employment Agreement effective as of August 2, 2021 between the Company and John M. Maraganore, Ph.D (Filed With SEC on August 3, 2021)

Amended and Restated Annual Incentive Program, as amended (Filed With SEC on February 11, 2021)

Change in Control Agreement dated November 2, 2020 by and between the Registrant and John M. Maraganore (Filed With SEC on February 11, 2021)

Co-Development Agreement between the Registrant and BXLS (Filed With SEC on November 5, 2020)

First Amendment to (Filed With SEC on November 5, 2020)

First Amendment to Lease entered into between the Registrant and RREEF America REIT II CORP. PPP dated September 30, 2020 (Filed With SEC on November 5, 2020)

Letter Agreement between the Registrant and Barry E. Greene dated August 26, 2020 (Filed With SEC on November 5, 2020)

Patent Cross-License Agreement dated April 3, 2020 between Dicerna Pharmaceuticals, Inc. and the Registrant (Filed With SEC on August 6, 2020)

Purchase and Sale Agreement dated April 10, 2020 between BX Bodyguard Royalties L.P. and the Registrant (Filed With SEC on August 6, 2020)

Description of Capital Stock (Filed With SEC on February 13, 2020)

Amended and Restated Annual Incentive Program (Filed With SEC on February 13, 2020)

Amendment to License and Collaboration Agreement, dated as of November 22, 2019 between the Registrant and The Medicines Company (Filed With SEC on February 13, 2020)

2018 Stock Incentive Plan, as amended (Filed With SEC on August 6, 2019)

Form of Ex-US Restricted/Performance Stock Unit Award Agreement under 2018 Stock Incentive Plan, as amended (Filed With SEC on August 6, 2019)

Amendment No. 3 entered into as of April 8, 2019 to the Master Collaboration Agreement dated as of January 11, 2014, as amended by Amendment No. 1 and Amendment No. 2, including... (Filed With SEC on August 6, 2019)

Stock Purchase Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)

Investor Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)

Amended and Restated ALN-AT3 Global License Terms entered into as of April 8, 2019 by and between the Registrant and Genzyme Corporation (Filed With SEC on August 6, 2019)

Amended and Restated Investor Agreement dated as of April 8, 2019 by and between the Registrant and Genzyme Corporation (Filed With SEC on August 6, 2019)

Amended and Restated 2004 Employee Stock Purchase Plan, as amended (Filed With SEC on May 2, 2019)

Underwriting Agreement, dated January 14, 2019, between Alnylam Pharmaceuticals, Inc. and Barclays Capital Inc (Filed With SEC on January 15, 2019)

Sixth Amendment to Lease, dated August 14, 2018, by and between the Registrant and ARE-MA Region No. 28, LLC (Filed With SEC on November 7, 2018)

Second Amendment to Lease, dated September 27, 2018, by and between Registrant and RREEF America REIT II CORP. PPP (Filed With SEC on November 7, 2018)

2018 Stock Incentive Plan (Filed With SEC on August 2, 2018)

Forms of Incentive Stock Option Agreement, Nonstatutory Stock Option Agreements, Restricted Stock Agreement and Restricted Stock Unit Award Agreement under 2018 Stock Incentive... (Filed With SEC on August 2, 2018)

Amendment No. 2 entered into as of January 6, 2018 to the Master Collaboration Agreement dated as of January 11, 2014, as amended by Amendment No. 1, including certain Regional,... (Filed With SEC on May 4, 2018)

Exclusive License Agreement entered into as of January 6, 2018 by and between the Registrant and Genzyme Corporation (Filed With SEC on May 4, 2018)

ALN-AT3 Global License Terms entered into as of January 6, 2018 by and between the Registrant and Genzyme Corporation (Filed With SEC on May 4, 2018)

Manufacturing Services Agreement effective as of March 28, 2018 by and between the Registrant and Agilent Technologies, Inc (Filed With SEC on May 4, 2018)

Underwriting Agreement, dated November 13, 2017, by and among Alnylam Pharmaceuticals, Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC, as representatives of the... (Filed With SEC on November 14, 2017)

Form of Change in Control Agreement (Filed With SEC on November 7, 2017)

ALNYLAM PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED 2009 STOCK INCENTIVE PLAN (Filed With SEC on August 9, 2017)

ALNYLAM PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under Second Amended and Restated 2009 Stock Incentive Plan (Filed With SEC on August 9, 2017)

ALNYLAM PHARMACEUTICALS, INC. AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on August 9, 2017)

300 Third Street Cambridge MA, 02142 main ###-###-#### fax ###-###-#### (Filed With SEC on August 9, 2017)

ALNYLAMPHARMACEUTICALS, INC. 5,000,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on May 25, 2017)

300 Third StreetCambridge MA, 02142main 617.551.8200fax ###-###-#### (Filed With SEC on February 15, 2017)

ALNYLAM PHARMACEUTICALS, INC. Form of Nonstatutory Stock OptionAgreement Non-Plan Inducement Grant (Filed With SEC on November 3, 2016)

FIRST AMENDMENT TO LEASE (Filed With SEC on November 3, 2016)

FORM OF DIRECTOR INDEMNIFICATION AGREEMENT (Filed With SEC on August 4, 2016)

CREDIT AGREEMENT Dated asof April 29, 2016 Among ALNYLAM U.S., INC., as theBorrower, ALNYLAM PHARMACEUTICALS, INC., as Parent and Parent Guarantor, and BANK OF AMERICA,N.A., as... (Filed With SEC on August 4, 2016)

CREDIT AGREEMENT Dated asof April 29, 2016 Among ALNYLAM U.S., INC., as the Borrower, ALNYLAMPHARMACEUTICALS, INC., as Parent and Parent Guarantor, and WELLS FARGO BANK,NATIONAL... (Filed With SEC on August 4, 2016)

Alnylam Pharmaceuticals, Inc. 2016 Annual Incentive Program (Filed With SEC on May 4, 2016)

ALNYLAM PHARMACEUTICALS, INC. AMENDED AND RESTATED 2009 STOCK INCENTIVE PLAN (including amendment through March 2, 2016) (Filed With SEC on May 4, 2016)

PURCHASE AND SALE AGREEMENT (Filed With SEC on May 4, 2016)

300 ThirdStreet Cambridge MA, 02142 main ###-###-#### fax ###-###-#### (Filed With SEC on February 12, 2016)

AMENDMENT NO. 1 TO MASTER COLLABORATION AGREEMENT (Filed With SEC on November 9, 2015)

AMENDMENTNUMBER ONE TO THE SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 9, 2015)

AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (Filed With SEC on November 9, 2015)

CONFIDENTIAL SETTLEMENT AGREEMENT AND MUTUAL RELEASE (Filed With SEC on October 2, 2015)

EXCLUSIVE LICENSE AGREEMENT FOR TUSCHL II UNITED STATES PATENTS AND PATENT APPLICATIONS (Filed With SEC on October 2, 2015)

ALNYLAM PHARMACEUTICALS, INC. AMENDED AND RESTATED 2009 STOCK INCENTIVE PLAN (Filed With SEC on August 7, 2015)

ALNYLAM PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under Amended and Restated 2009 Stock Incentive Plan (Filed With SEC on August 7, 2015)

ALNYLAM PHARMACEUTICALS, INC. Restricted Stock Agreement (Filed With SEC on August 7, 2015)

ALNYLAM PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2009 Stock Incentive Plan (Filed With SEC on August 7, 2015)

LEASE RREEF AMERICA REIT IICORP. PPP, Landlord, and ALNYLAM PHARMACEUTICALS,INC., Tenant RiverfrontOffice Park Cambridge, Massachusetts TABLE OF CONTENTS (continued) (Filed With SEC on August 7, 2015)

LEASE by and between BMR-675 WEST KENDALL STREET LLC, a Delaware limited liability company and ALNYLAMPHARMACEUTICALS, INC., a Delaware corporation Table of Contents (Filed With SEC on August 7, 2015)

CERTIFICATE OF ELIMINATION OF THE SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF ALNYLAM PHARMACEUTICALS, INC. Pursuant to Section 151(g) of the General Corporation Law ofthe... (Filed With SEC on July 14, 2015)

Alnylam Pharmaceuticals, Inc. 2015 Annual Incentive Program (Filed With SEC on May 8, 2015)

SECOND AMENDEDAND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 8, 2015)

AMENDMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 8, 2015)

ALNYLAMPHARMACEUTICALS, INC. 4,736,842 Shares of Common Stock Underwriting Agreement (Filed With SEC on January 26, 2015)

LETTER AGREEMENT (Filed With SEC on November 6, 2014)

ALNYLAM PHARMACEUTICALS, INC. AMENDED AND RESTATED 2004 STOCK INCENTIVE PLAN (Filed With SEC on August 8, 2014)

ALNYLAM PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under Amended and Restated 2004 Stock Incentive Plan (Filed With SEC on August 8, 2014)

ALNYLAM PHARMACEUTICALS, INC. 2009 STOCK INCENTIVE PLAN, AS AMENDED (Filed With SEC on August 8, 2014)

ALNYLAM PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2009 Stock Incentive Plan (Filed With SEC on August 8, 2014)

ALNYLAM PHARMACEUTICALS, INC. Restricted Stock Agreement (Filed With SEC on August 8, 2014)

ALNYLAM PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2009 Stock Incentive Plan (Filed With SEC on August 8, 2014)

STOCK PURCHASE AGREEMENT by and among ALNYLAMPHARMACEUTICALS, INC., SIRNA THERAPEUTICS, INC., MERCK SHARP & DOHME CORP., and solely for purposes of Sections 3.19, 5.2, 5.6,... (Filed With SEC on May 9, 2014)

Alnylam Pharmaceuticals, Inc. 2014 Annual Incentive Program (Filed With SEC on May 9, 2014)

STOCK PURCHASE AGREEMENT By and Between GENZYMECORPORATION AND ALNYLAM PHARMACEUTICALS, INC. Dated as of January 11, 2014 TABLE OF CONTENTS (Filed With SEC on May 9, 2014)

INVESTOR AGREEMENT BYAND BETWEEN GENZYME CORPORATION AND ALNYLAMPHARMACEUTICALS, INC. DATED AS OF FEBRUARY 27, 2014 (Filed With SEC on May 9, 2014)

FIRST AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on February 27, 2014)

MASTER SERVICES AGREEMENT Between Medpace, Inc. an Ohio Corporation 4620 WesleyAvenue Cincinnati, Ohio 45212 (MEDPACE) and Alnylam Pharmaceuticals, Inc. 300Third Street Cambridge,... (Filed With SEC on February 20, 2014)

ALNYLAM PHARMACEUTICALS, INC. 2009 STOCK INCENTIVE PLAN, AS AMENDED (Filed With SEC on August 9, 2013)

Alnylam Pharmaceuticals, Inc. 2013 Annual Incentive Program (Filed With SEC on May 7, 2013)

LICENSE AND COLLABORATION AGREEMENT by and between ALNYLAM PHARMACEUTICALS, INC. and THE MEDICINES COMPANY (Filed With SEC on May 7, 2013)

CONSULTING AGREEMENT (Filed With SEC on February 19, 2013)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on February 19, 2013)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions (Filed With SEC on February 19, 2013)

65 Hayden Avenue, Lexington, MA 02421 P ###-###-#### F ###-###-#### www.cubist.com (Filed With SEC on February 19, 2013)

ALNYLAM PHARMACEUTICALS, INC. 8,000,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on January 16, 2013)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on November 5, 2012)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on November 5, 2012)

[Signature Page follows] (Filed With SEC on November 5, 2012)

Alnylam Pharmaceuticals, Inc. 2012 Annual Incentive Program (Filed With SEC on May 3, 2012)

Confidential Materials omitted and filed separately with the Securities andExchange Commission. Asterisks denote omissions. LEASE by and between BMR-FRESH POND RESEARCH PARK LLC,... (Filed With SEC on May 3, 2012)

CONSULTING AGREEMENT (Filed With SEC on April 23, 2012)

ALNYLAM PHARMACEUTICALS, INC. 7,500,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on February 15, 2012)

FOURTH AMENDMENT TO LEASE (Filed With SEC on February 13, 2012)

SUBLEASE (Filed With SEC on February 13, 2012)

EX-101 INSTANCE DOCUMENT (Filed With SEC on November 3, 2011)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on June 29, 2011)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. Alnylam Tekmira Protiva UBC AlCana Supplemental... (Filed With SEC on June 29, 2011)

EX-101 INSTANCE DOCUMENT (Filed With SEC on May 5, 2011)

EX-101 INSTANCE DOCUMENT (Filed With SEC on February 18, 2011)

EX-10.2 Third Amendment to Lease, dated May 11, 2010 (Filed With SEC on August 5, 2010)

EX-10.9 Forms of Incentive Stock Option Agreement and Nonstatutory Stock Option Agreement (Filed With SEC on February 26, 2010)

EX-10.16 2010 Annual Incentive Program (Filed With SEC on February 26, 2010)

EX-10.39 Collaboration Agreement entered into as of October 29, 2009 (Filed With SEC on February 26, 2010)

EX-10.40 First Amendment to License and Collaboration Agreement entered into as of November 2, 2009 (Filed With SEC on February 26, 2010)

EX-10.1 Letter Agreement between the Registrant and John A. Schmidt, Jr., M.D (Filed With SEC on November 4, 2009)

Ex-10.1 Amended and Restated 2004 Stock Incentive Plan (Filed With SEC on August 7, 2009)

Ex-10.2 2009 Stock Incentive Plan (Filed With SEC on August 7, 2009)

Ex-10.3 Amended and Restated Strategic Collaboration and License Agreement effective as of April 28, 2009 between Isis Pharmaceuticals, Inc. and the Registrant (Filed With SEC on August 7, 2009)

Ex-10.4 Second Amendment to Lease, dated June 26, 2009, by and between the Registrant and ARE-MA Region No. 28, LLC (Filed With SEC on August 7, 2009)

Ex-10.1 2009 Annual Incentive Program (Filed With SEC on May 8, 2009)

Ex-10.2 License and Collaboration Agreement between the Registrant and Cubist (Filed With SEC on May 8, 2009)

Ex-10.23 Research Collaboration and License Agreement (Filed With SEC on March 2, 2009)

Ex-10.26 License and Collaboration Agreement (Filed With SEC on March 2, 2009)

EX-10.3 2004 Stock Incentive Plan, as amended (Filed With SEC on March 10, 2008)

EX-10.8 2004 Employee stock Purchase Plan, as amended (Filed With SEC on March 10, 2008)

Ex-10.1 License and Collaboration Agreement, entered into as of July 8, 2007, by and among F. Hoffmann-La Roche, Ltd, Hoffman-La Roche Inc., the Registrant and, for limited... (Filed With SEC on November 8, 2007)

Ex-10.2 Common Stock Purchase Agreement dated as of July 8, 2007 between the Registrant and Roche Finance Ltd (Filed With SEC on November 8, 2007)

Ex-10.3 Share Purchase Agreement, dated as of July 8, 2007, among Alnylam Europe AG, the Registrant and Roche Pharmaceuticals GmbH (Filed With SEC on November 8, 2007)

Ex-10.4 Amended and Restated Collaboration Agreement, entered into as of July 27, 2007, by and between the Registrant and Medtronic, Inc (Filed With SEC on November 8, 2007)

Ex-10.5 License and Collaboration Agreement, entered into as of September 6, 2007, by and among the Registrant, Isis Pharmaceuticals, Inc. and Regulus Therapeutics LLC (Filed With SEC on November 8, 2007)

Ex-10.6 Limited Liability Company Agreement of Regulus Therapeutics LLC, dated as of September 6, 2007 (Filed With SEC on November 8, 2007)

Ex-10.7 Termination Agreement, dated as of September 18, 2007, by and between Merck & Co., Inc. and the Registrant (Filed With SEC on November 8, 2007)

EX-1.1 Underwriting Agreement, dated December 12, 2006 (Filed With SEC on December 13, 2006)

Ex-10.1 Collaboration and License Agreement by and between the Registrant and Biogen Idec MA. Inc. dated September 20, 2006 (Filed With SEC on November 9, 2006)

Ex-10.2 Letter Agreement by and between the Registrant and Vincent J. Miles effective as of October 20, 2006 (Filed With SEC on November 9, 2006)

EX-10.1 AMEND. & RESTATED RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on August 4, 2006)

EX-10.2 TERMINATION AGREEMENT (Filed With SEC on August 4, 2006)

EX-10.3 AMENDMENT NO. 2 TO ADDENDUM RE: INFLUENZA PROGRAM (Filed With SEC on May 9, 2006)

Ex-10.1 Master Security Agreement (Filed With SEC on April 6, 2006)

EX-10.1 First Amendment to Lease, effective as of March 16, 2006 (Filed With SEC on March 17, 2006)

Ex-10.39 Amendment No. 1 to Addendum (Filed With SEC on March 16, 2006)

EX-10.1 RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on October 12, 2005)

EX-10.1 STOCK PURCHASE AGREEMENT (Filed With SEC on September 12, 2005)

EX-10.2 INVESTOR RIGHTS AGREEMENT (Filed With SEC on September 12, 2005)

EX-10.3 RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on September 12, 2005)

EX-10.3 Forms of Incentive Stock Option (Filed With SEC on August 11, 2005)

EX-10.6 Amendment No. 1 to dated August 2,2004 (Filed With SEC on August 11, 2005)

EX-10.8 Agreement Garching Innovation GmbH (Filed With SEC on August 11, 2005)

Ex-4.1 Rights Agreement (Filed With SEC on July 14, 2005)

EX-10.1 - Form of Nonstatutory Stock Option Agreement (Filed With SEC on July 13, 2005)

EX-10.2 - Form of Restricted Stock Agreement (Filed With SEC on July 13, 2005)

Ex-10.1 Amendment No. 02 to Loan and Security Agreement (Filed With SEC on June 24, 2005)

EX-10.1 SUMMARY OF CASH COMPENSATION FOR DIRECTORS (Filed With SEC on June 10, 2005)

EX-10.2 2004 STOCK INCENTIVE PLAN (Filed With SEC on June 10, 2005)

Ex-10.1 Collaboration Agreement effective as of February 8, 2005 (Filed With SEC on May 16, 2005)

Ex-10.6 Summary of Cash Compensation Paid to Directors (Filed With SEC on March 30, 2005)

Ex-10.1 Form of Nonstatutory Stock Option Agreement (Filed With SEC on December 28, 2004)

EX-1.1 Amendment to Underwriting Agreement (Filed With SEC on November 4, 2004)

EX-10.1 COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on August 12, 2004)

EX-1.1 UNDERWRITING AGREEMENT (Filed With SEC on May 10, 2004)

EX-4.1 SPECIMEN CERTIFICATE (Filed With SEC on May 10, 2004)

EX-10.1 2002 EMP, DIRECTOR & CONSULTANT STOCK PLAN (Filed With SEC on May 10, 2004)

EX-10.2 2003 EMP, DIRECTOR & CONSULTANT STOCK PLAN (Filed With SEC on May 10, 2004)

EX-10.3 2004 STOCK INCENTIVE PLAN (Filed With SEC on May 10, 2004)

EX-10.4 2004 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on May 10, 2004)

Ex-4.1 Specimen Certificate evidencing shares (Filed With SEC on April 29, 2004)

Ex-10.2 2003 Stock Plan, as amended (Filed With SEC on April 29, 2004)

Ex-10.3 2004 Stock Incentive Plan (Filed With SEC on April 29, 2004)

Ex-10.19 Co-exclusive License Agreement (Filed With SEC on April 29, 2004)

Ex-10.26 Agreement with Perini Building Company (Filed With SEC on April 29, 2004)

EX-10.1 2002 EMPLOYEE, DIRECTOR STOCK PLAN (Filed With SEC on April 6, 2004)

EX-10.2 2003 EMPLOYEE, DIRECTOR STOCK PLAN (Filed With SEC on April 6, 2004)

EX-10.3 2004 STOCK INCENTIVE PLAN (Filed With SEC on April 6, 2004)

EX-10.4 2004 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on April 6, 2004)

EX-10.11 LOAN AND SECURITY AGREEMENT (Filed With SEC on April 6, 2004)

EX-10.12 WARRANT TO PURCHASE PREFERRED STOCK (Filed With SEC on April 6, 2004)

EX-10.24 STRATEGIC COLLABORATION & LICENSE (Filed With SEC on April 6, 2004)

EX-10.25 INVESTOR RIGHTS AGREEMENT (Filed With SEC on April 6, 2004)